International Journal of Drug Delivery Technology
Volume 14, Issue 1

Desitometric Development and Validation for Simultaneous Determination of Antiretroviral Drugs Lamivudine, Zidovudine and Nevirapine in Fixed-Dose Combination Tablets

Ashwini Shelke*, Tushar Lokhande

Mahatma Gandhi Vidyamandir’s Pharmacy College, Panchavati, Nashik, Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India.

Received: 15th August, 2023; Revised: 08th January, 2024; Accepted: 21st February, 2024; Available Online: 25th March, 2024

ABSTRACT

A cutting-edge high-performance thin layer chromatography (HPTLC) approach designed for simultaneous measurement of tablets containing drugs like lamivudine, nevirapine, and zidovudine. Chromatograms were performed employing chloroform and methanol (8:2 v/v) on pre-coated silica gel aluminum thin-layer chromatography (TLC) plates. The data was quantified using the optical density absorbance mode at 271 nm. The Rf values for lamivudine, zidovudine, and nevirapine were 0.140, 0.523, and 0.678, respectively. Linearity was found for lamivudine, zidovudine and nevirapine at concentrations of 150 to 900 ng band-1, 300 to 1800 and 200 to 1200 ng band-1, respectively. Lamivudine had a lower limit of detection (LLoD) of 27.36 ng band-1 and a lower limit of quantitation (LLoQ) of 82.91 ng band-1, whereas zidovudine had LoQs of 64.13 ng band-1 and

194.34 ng band-1. For nevirapine, the values were 35.52 and 107.64 ng band-1, respectively. Lamivudine had a lower LoD of 27.36 ng band-1 and a lower LoQ of 82.91 ng band-1, whereas zidovudine had LoQs of 64.13 and 194.34 ng band-1. For nevirapine, the values were 35.52 and 107.64 ng band-1, respectively. The recovery, specificity, and accuracy of this device have been demonstrated. This new formulation evaluated market tablet formulations of the above drugs (Duovir, Cipla Ltd.). The developed method demonstrated the ability to simultaneously identify these drugs from quantitative data without interference.

Keywords: HPTLC, Validation, Lamivudine, Nevirapine, and Zidovudine, Anti-viral. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.50

How to cite this article: Shelke A, Lokhande T. Desitometric Development and Validation for Simultaneous Determination of Antiretroviral Drugs Lamivudine, Zidovudine and Nevirapine in Fixed-Dose Combination Tablets. International Journal of Drug Delivery Technology. 2024;14(1):352-356.

REFERENCES
  1. Vekatesh P, Daggumati M. Development, and Validation of a normal-phase HPTLC method for the simultaneous analysis of Lamivudine and Zidovudine in fixed-dose combination tablets. Journal of Pharmaceutical Analysis 2009; 2(2): 152-155.
  2. Solomon G, Hymete A, Abdel MI, Adnan AB. HPTLC- densitometric method development and validation for simultaneous determination of Lamivudine, Nevirapine and Zidovudine in fixed dose combinations. Thai Journal of Pharmaceutical Sciences 2011; 35: 77-88.
  3. Shelke AV, Lokhande TN, Pardeshi V. Characterization of impurities in Reverse Transcriptase inhibitors by profiling techniques. Asian Pacific Journal of Health sciences 2022; 9(4): 18-25.
  4. Baluchová S, Mamaloukou A, Rombert HJM, Josephus GB. Modification-free boron-doped diamond as a sensing material for direct and reliable detection of the antiretroviral drug Electrochimica Acta2023; 450: 142238.
  5. Chawla A, Wang C, Patton C, Murray M, Punekar Y, A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infectious Diseases & Therapy 2018; 7(2): 183–195.
  6. Kaale E, Risha P, Reich E, Layloff TP. An Inter laboratory investigation on the use of high-performance thin layer chromatography to perform assays of Lamivudine-Zidovudine, Metronidazole, Nevirapine, and Quinine composite samples. Journal of AOAC International 2010; 93(6): 1836-43.
  7. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral AIDS 2014; 28(8): 1193–1202.
  8. Deeks SG, Lewin SR, Havlir The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382(9903):1525–1533.
  9. Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi E, Antinori A, Gatti F. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. HIV Med. 2010;11(2):104–113.
  10. Joshi A, Adeyeye MC. Reversed Phase LC-UV Method Development and Validation for Simultaneous Determination of Three Antiretrovirals: Lamivudine, Zidovudine, Nevirapine and Possible Degradants in a Fixed Dose Pharmaceutical Product. Journal of Pharmaceutical Technology & Drug Research 2012; 1(1):4.
  11. European AIDS Clinical Guidelines version 9.0. October 2017
  12. Jourjy J, Dahl K, Huesgen E. Antiretroviral treatment efficacy and safety in older HIV-infected Pharmacotherapy 2015; 35(12): 1140–1151.
  13. Garcia-Trejo JJ, Ortega R, Zarco-Zavala Putative Repurposing of Lamivudine, a Nucleoside/ Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients. Frontiers in Oncology 2021; 11: 664794.
  14. International Conference on Harmonization (ICH), Q2A: Texton Validation of Analytical Procedure USFDA federal register, 1995, vol 60, p.11260
  15. Guideline IHT, Validation of analytical procedures: text and methodology Q2 (R1). International conference on harmonization, Geneva, Switzerland; 2005.
  16. ICH harmonised tripartite guideline: Stability Testing of New Drug Substances and Products Q1A (R2), step-4, Geneva, Switzerland, 2003.